Ono Pharmaceutical (OTCMKTS:OPHLF) Announces Earnings Results, Beats Estimates By $0.11 EPS

Ono Pharmaceutical (OTCMKTS:OPHLF) issued its quarterly earnings data on Monday. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.11, Zacks reports. Ono Pharmaceutical had a return on equity of 6.13% and a net margin of 9.75%.The business had revenue of $892.70 million for the quarter, compared to analysts’ expectations of $727.58 million.

Ono Pharmaceutical Stock Performance

Shares of OPHLF stock opened at $15.22 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.99 and a quick ratio of 2.50. The business has a 50-day moving average of $13.65 and a 200 day moving average of $12.20. The stock has a market capitalization of $7.15 billion, a PE ratio of 21.74 and a beta of 0.25. Ono Pharmaceutical has a 1-year low of $9.20 and a 1-year high of $15.22.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.